ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.67 No.6 November 2019

Antibacterial activity of colistin against clinical isolates from patients with infections in Japan -Outcomes of special drug use investigation on antibacterial activity (annual changes)-

Atsuko Ishida1), Yasuo Nakajima2), Terufumi Hara1) and Daisaku Yasui3)

1)Post-marketing Surveillance Department, GlaxoSmithKline K.K., Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, Japan
2)MSL Immuno-Inflammation & Infectious Diseases Department, GlaxoSmithKline K.K.
3)PV Medical Evaluation Department, GlaxoSmithKline K.K.

Abstract

Colistin (CL), a polypeptide antimicrobial agent, was approved in Japan in 2015 for the treatment of infections due to multidrug-resistant Gram-negative bacilli. Subsequent to its approval, we conducted a 3-year special drug use investigation (2015-2018), wherein we monitored and assessed the annual changes of the antibacterial activity of CL and other antimicrobial agents in clinical isolates obtained from Japanese infectious disease patients. We isolated 150 strains of multidrug-resistant Pseudomonas aeruginosa (MDRP) and 11 strains of multidrug-resistant Acinetobacter species (MDRA). Multidrug resistance was defined according to the Infectious Diseases Control Law of Japan. Susceptibility tests were performed by the broth microdilution method in accordance with the Clinical and Laboratory Standards Institute M7-A10 standard. The MIC ranges of CL for the MDRP and MDRA strains during the 3-year study period were 0.25-2 μg/mL and 0.5-2 μg/mL, respectively. There were no remarkable annual changes in the MICs during the study period.
In the present study, no tendency towards decrease of the antibacterial activity of CL against MDRP and MDRA was observed during the 3-year study period, from 2015 to 2018.

Key word

colistin, MIC, multidrug resistance, Pseudomonas aeruginosa, Acinetobacter

Received

January 21, 2019

Accepted

May 8, 2019

Jpn. J. Chemother. 67 (6): 645-650, 2019